Search

Your search keyword '"de Haas, Robbert"' showing total 363 results
Start Over Author "de Haas, Robbert"
363 results on '"de Haas, Robbert"'

51. A dual-tracer approach using [11C]CH and [18F]FDG in HCC clinical decision making.

Author

Veenstra, Emile B., Ruiter, Simeon J. S., de Haas, Robbert J., de Jong, Koert P., Erba, Paola A., Dierckx, Rudi A. J. O., and Noordzij, Walter

Subjects
DECISION making, POSITRON emission tomography, PATIENT decision making, TUMOR markers, COMPUTED tomography, BIOMARKERS
Abstract

Background: Early detection of recurrent or progressive HCC remains the strongest prognostic factor for survival. Dual tracer PET/CT imaging with [11C]CH and [18F]FDG can further increase detection rates as both tracers entail different metabolic pathways involved in HCC development. We investigated dual-tracer PET/CT in clinical decision making in patients suspected of recurrent or progressive HCC. All HCC patients who underwent both [11C]CH and [18F]FDG PET/CT in our institute from February 2018 to December 2021 were included. Both tracer PET/CT were within 4 weeks of each other with at least 6-month follow-up. Patients underwent dual tracer PET/CT because of unexplained and suspicious CT/MRI or sudden rise of serum tumour markers. A detected lesion was considered critical when the finding had prognostic consequences leading to treatment changes. Results: Nineteen patients who underwent [11C]CH and [18F]FDG PET/CT were included of which all but six patients were previously treated for HCC. Dual-tracer critical finding detection rate was 95%, with [18F]FDG 68%, and [11C]CH 84%. Intrahepatic HCC recurrence finding rate was 65% for both tracers. [18F]FDG found more ablation site recurrences (4/5) compared to [11C]CH (2/5). Only [11C]CH found two needle tract metastases. Both tracers found 75% of the positive lymph nodes. Two new primary tumours were found, one by [18F]FDG and both by [11C]CH. Conclusions: Our study favours a dual-tracer approach in HCC staging in high-risk patients or when conventional imaging is non-conclusive. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

56. Study protocol for a multicentre nationwide prospective cohort study to investigate the natural course and clinical outcome in benign liver tumours and cysts in the Netherlands: the BELIVER study

Author

Furumaya, Alicia, primary, Haring, Martijn P D, additional, van Rosmalen, Belle V, additional, Klompenhouwer, Anne J, additional, Besselink, Marc G, additional, de Man, Robert A, additional, IJzermans, Jan N M, additional, Thomeer, Maarten G J, additional, Kramer, Matthijs, additional, Coolsen, Mariëlle M E, additional, Tushuizen, Maarten E, additional, Schaapherder, Alexander F, additional, de Haas, Robbert J, additional, Duiker, Evelien W, additional, Kazemier, Geert, additional, van Delden, Otto M, additional, Verheij, Joanne, additional, Takkenberg, R Bart, additional, Cuperus, Frans J C, additional, De Meijer, Vincent E, additional, and Erdmann, Joris I, additional

Published
2022
Full Text
View/download PDF

62. Hepatic artery and portal vein Doppler ultrasound reference values in children aged 0–17 years old.

Author

Verhagen, Martijn V, Kwee, Thomas C, and de Haas, Robbert J

Subjects
HEPATIC artery, REFERENCE values, RETROSPECTIVE studies, ACQUISITION of data, REGRESSION analysis, PORTAL vein, DOPPLER ultrasonography, MEDICAL records, DESCRIPTIVE statistics, CHILDREN
Abstract

Introduction: Doppler ultrasound of the portal vein peak systolic velocity and hepatic artery peak systolic velocity and resistive index in children is often performed during abdominal ultrasound for the assessment of liver and other abdominal pathology. However, evidence-based reference values are not available. We aimed to determine these reference values and to investigate whether they are age-dependent. Methods: Children who underwent abdominal ultrasound between 2020 and 2021 were retrospectively identified. Patients without hepatic or cardiac abnormalities at the time of ultrasound or during at least 3 months follow-up were eligible for the study. Ultrasound without hepatic hilum portal vein peak systolic velocity and/or hepatic artery peak systolic velocity and resistive index measurements were excluded. Age-dependent changes were analyzed using linear regression. Normal range reference values were described using percentiles for all ages, and for age subgroups. Results: One-hundred ultrasound examinations performed in 100 healthy children aged 0–17.9 years (median 7.8 years, interquartile range 1.1–14.1 years) were included. Ninety-nine portal vein peak systolic velocity and 80 hepatic artery peak systolic velocity and resistive index measurements were obtained. There was no significant association between portal vein peak systolic velocity and age (β = −0.056, p = 0.68). There were significant associations between age and hepatic artery peak systolic velocity, and between age and hepatic artery resistive index (β = −0.873, p = 0.04 and β = −0.004, p < 0.001, respectively). Detailed reference values were provided for all ages, and for age subgroups. Conclusion: Reference values for the hepatic hilum portal vein peak systolic velocity, hepatic artery peak systolic velocity, and hepatic artery resistive index in children were established. Portal vein peak systolic velocity is not age-dependent, whereas hepatic artery peak systolic velocity and hepatic artery resistive index decrease when children get older. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

64. Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trial

Author

Smits, F Jasmijn, primary, Henry, Anne Claire, additional, Besselink, Marc G, additional, Busch, Olivier R, additional, van Eijck, Casper H, additional, Arntz, Mark, additional, Bollen, Thomas L, additional, van Delden, Otto M, additional, van den Heuvel, Daniel, additional, van der Leij, Christiaan, additional, van Lienden, Krijn P, additional, Moelker, Adriaan, additional, Bonsing, Bert A, additional, Borel Rinkes, Inne H, additional, Bosscha, Koop, additional, van Dam, Ronald M, additional, Derksen, Wouter J M, additional, den Dulk, Marcel, additional, Festen, Sebastiaan, additional, Groot Koerkamp, Bas, additional, de Haas, Robbert J, additional, Hagendoorn, Jeroen, additional, van der Harst, Erwin, additional, de Hingh, Ignace H, additional, Kazemier, Geert, additional, van der Kolk, Marion, additional, Liem, Mike, additional, Lips, Daan J, additional, Luyer, Misha D, additional, de Meijer, Vincent E, additional, Mieog, J Sven, additional, Nieuwenhuijs, Vincent B, additional, Patijn, Gijs A, additional, te Riele, Wouter W, additional, Roos, Daphne, additional, Schreinemakers, Jennifer M, additional, Stommel, Martijn W J, additional, Wit, Fennie, additional, Zonderhuis, Babs A, additional, Daamen, Lois A, additional, van Werkhoven, C Henri, additional, Molenaar, I Quintus, additional, van Santvoort, Hjalmar C, additional, Blomjous, JG, additional, de Boer, MT, additional, van den Boezem, P, additional, Bouwense, S, additional, Bruijnen, R, additional, Buis, CI, additional, del Chiaro, M, additional, Coene, PP, additional, Coolsen, M, additional, Daams, F, additional, Dejong, K, additional, Draaisma, W, additional, Eker, HH, additional, Elsen, AH, additional, Gerhards, MF, additional, Hartog, H, additional, Hoogwater, FJ, additional, Imani, F, additional, Jenniskens, S, additional, de Jong, KP, additional, Karsten, TM, additional, Klaase, JM, additional, de Kleine, RHJ, additional, van Laarhoven, CJ, additional, van der Lelij, H, additional, Manusama, ER, additional, Meerdink, M, additional, Meijerink, M, additional, Nederend, J, additional, Nijkamp, MW, additional, Nota, CL, additional, Porte, RJ, additional, Reef, J, additional, de Reuver, P, additional, van Rijswijk, C, additional, Romkens, T, additional, Rupert, C, additional, van der Schelling, GP, additional, Serafino, JP, additional, Vos, LD, additional, Vriens, MR, additional, Beers-Vural, E, additional, Wagtenberg, JM, additional, Wijsman, JH, additional, de Wilde, RF, additional, Wolfgang, CL, additional, and Zeh, HJ, additional

Published
2022
Full Text
View/download PDF

65. Design of Polypeptides Self-Assembling into Antifouling Coatings: Exploiting Multivalency

Author

Alvisi, Nicolò, Zheng, Chuanbao, Lokker, Meike, Boekestein, Victor, de Haas, Robbert, Albada, Bauke, de Vries, Renko, Alvisi, Nicolò, Zheng, Chuanbao, Lokker, Meike, Boekestein, Victor, de Haas, Robbert, Albada, Bauke, and de Vries, Renko

Abstract

We propose to exploit multivalent binding of solid-binding peptides (SBPs) for the physical attachment of antifouling polypeptide brushes on solid surfaces. Using a silica-binding peptide as a model SBP, we find that both tandem-repeated SBPs and SBPs repeated in branched architectures implemented via a multimerization domain work very well to improve the binding strength of polypeptide brushes, as compared to earlier designs with a single SBP. At the same time, for many of the designed sequences, either the solubility or the yield of recombinant production is low. For a single design, with the domain structure B-M-E, both solubility and yield of recombinant production were high. In this design, B is a silica-binding peptide, M is a highly thermostable, de novo-designed trimerization domain, and E is a hydrophilic elastin-like polypeptide. We show that the B-M-E triblock polypeptide rapidly assembles into highly stable polypeptide brushes on silica surfaces, with excellent antifouling properties against high concentrations of serum albumin. Given that SBPs attaching to a wide range of materials have been identified, the B-M-E triblock design provides a template for the development of polypeptides for coating many other materials such as metals or plastics.

Published
2022

66. Study protocol for a multicentre nationwide prospective cohort study to investigate the natural course and clinical outcome in benign liver tumours and cysts in the Netherlands:the BELIVER study

Author

Furumaya, Alicia, Haring, Martijn P.D., Van Rosmalen, Belle V., Klompenhouwer, Anne J., Besselink, Marc G., De Man, Robert A., Ijzermans, Jan N.M., Thomeer, Maarten G.J., Kramer, Matthijs, Coolsen, Mariëlle M.E., Tushuizen, Maarten E., Schaapherder, Alexander F., De Haas, Robbert J., Duiker, Evelien W., Kazemier, Geert, Van Delden, Otto M., Verheij, Joanne, Takkenberg, R. Bart, Cuperus, Frans J.C., De Meijer, Vincent E., Erdmann, Joris I., Furumaya, Alicia, Haring, Martijn P.D., Van Rosmalen, Belle V., Klompenhouwer, Anne J., Besselink, Marc G., De Man, Robert A., Ijzermans, Jan N.M., Thomeer, Maarten G.J., Kramer, Matthijs, Coolsen, Mariëlle M.E., Tushuizen, Maarten E., Schaapherder, Alexander F., De Haas, Robbert J., Duiker, Evelien W., Kazemier, Geert, Van Delden, Otto M., Verheij, Joanne, Takkenberg, R. Bart, Cuperus, Frans J.C., De Meijer, Vincent E., and Erdmann, Joris I.

Abstract

Introduction Benign liver tumours and cysts (BLTCs) comprise a heterogeneous group of cystic and solid lesions, including hepatic haemangioma, focal nodular hyperplasia and hepatocellular adenoma. Some BLTCs, for example, (large) hepatocellular adenoma, are at risk of complications. Incidence of malignant degeneration or haemorrhage is low in most other BLTCs. Nevertheless, the diagnosis BLTC may carry a substantial burden and patients may be symptomatic, necessitating treatment. The indications for interventions remain matter of debate. The primary study aim is to investigate patient-reported outcomes (PROs) of patients with BLTCs, with special regards to the influence of invasive treatment as compared with the natural course of the disease. Methods and analysis A nationwide observational cohort study of patients with BLTC will be performed between October 2021 and October 2026, the minimal follow-up will be 2 years. During surveillance, a questionnaire regarding symptoms and their impact will be sent to participants on a biannual basis and more often in case of invasive intervention. The questionnaire was previously developed based on PROs considered relevant to patients with BLTCs and their caregivers. Most questionnaires will be administered by computerised adaptive testing through the Patient-Reported Outcomes Measurement Information System. Data, such as treatment outcomes, will be extracted from electronic patient files. Multivariable analysis will be performed to identify patient and tumour characteristics associated with significant improvement in PROs or a complicated postoperative course. Ethics and dissemination The study was assessed by the Medical Ethics Committee of the University Medical Center Groningen and the Amsterdam UMC. Local consultants will provide information and informed consent will be asked of all patients. Results will be published in a peer-reviewed journal. Study registration NL8231 - 10 December 2019; Netherlands Trial Register.

Published
2022

69. Utility of preoperative CT-based body metrics in relation to postoperative complications in pediatric liver transplant recipients

Author

Verhagen, Martijn V, Levolger, Stef, Hulshoff, Jan Binne, Werner, Maureen J M, van der Doef, Hubert P J, Viddeleer, Alain R, de Kleine, Ruben H, and de Haas, Robbert J

Abstract

BACKGROUND: Computed tomography (CT) derived body metrics such as skeletal muscle index (SMI), psoas muscle index (PMI), and subcutaneous fat index (ScFI) are measurable components of sarcopenia, frailty, and nutrition. While these body metrics are advocated in adults for predicting postoperative outcomes after liver transplantation (LT), little is known about the value in pediatric populations. This study assessed the relation between preoperative CT-based body metrics and postoperative short-term outcomes in pediatric LT recipients. METHODS: Patients aged 0-18 years who underwent a primary LT were retrospectively included (N=101, median age 0.5 years, range 0.2-17.1). SMI, PMI, and ScFI were derived from preoperative axial CT slices. Postoperative outcomes and complications within 90 days were correlated with the CT-based body metrics. To classify postoperative infections, the Clavien-Dindo (CD) classification was used. Subgroup analyses were performed for age groups (10 years old). An optimal threshold for test performance was defined using Youden's J-statistic and receiver operating characteristic curve as appropriate. RESULTS: ScFI was significantly (P=0.001) correlated with moderate to severe postoperative infections (CD grade 3-5) in children

Published
2021

72. Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin‐rich thrombus

Author

Driever, Ellen G., primary, von Meijenfeldt, Fien A., additional, Adelmeijer, Jelle, additional, de Haas, Robbert J., additional, van den Heuvel, Marius C., additional, Nagasami, Chandrasekaran, additional, Weisel, John W., additional, Fondevila, Constantino, additional, Porte, Robert J., additional, Blasi, Anabel, additional, Heaton, Nigel, additional, Gregory, Stephen, additional, Kane, Pauline, additional, Bernal, William, additional, Zen, Yoh, additional, and Lisman, Ton, additional

Published
2021
Full Text
View/download PDF

73. Gallbladder reporting and data system (GB-RADS) for risk stratification of gallbladder wall thickening on ultrasonography: an international expert consensus

Author

Gupta, Pankaj, primary, Dutta, Usha, additional, Rana, Pratyaksha, additional, Singhal, Manphool, additional, Gulati, Ajay, additional, Kalra, Naveen, additional, Soundararajan, Raghuraman, additional, Kalage, Daneshwari, additional, Chhabra, Manika, additional, Sharma, Vishal, additional, Gupta, Vikas, additional, Yadav, Thakur Deen, additional, Kaman, Lileshwar, additional, Irrinki, Santosh, additional, Singh, Harjeet, additional, Sakaray, Yashwant, additional, Das, Chandan Krishuna, additional, Saikia, Uma, additional, Nada, Ritambhara, additional, Srinivasan, Radhika, additional, Sandhu, Manavjit Singh, additional, Sharma, Raju, additional, Shetty, Nitin, additional, Eapen, Anu, additional, Kaur, Harmeet, additional, Kambadakone, Avinash, additional, de Haas, Robbert, additional, Kapoor, Vinay K., additional, Barreto, Savio George, additional, Sharma, Atul K., additional, Patel, Amol, additional, Garg, Pramod, additional, Pal, Sujoy K., additional, Goel, Mahesh, additional, Patkar, Shraddha, additional, Behari, Anu, additional, Agarwal, Anil K., additional, Sirohi, Bhawna, additional, Javle, Milind, additional, Garcea, Giuseppe, additional, Nervi, Flavio, additional, Adsay, Volkan, additional, Roa, Juan Carlos, additional, and Han, Ho-Seong, additional

Published
2021
Full Text
View/download PDF

74. 3D Quantitative Ablation Margins for Prediction of Ablation Site Recurrence After Stereotactic Image-Guided Microwave Ablation of Colorectal Liver Metastases: A Multicenter Study

Author

Ruiter, Simeon J. S., primary, Tinguely, Pascale, additional, Paolucci, Iwan, additional, Engstrand, Jennie, additional, Candinas, Daniel, additional, Weber, Stefan, additional, de Haas, Robbert J., additional, de Jong, Koert P., additional, and Freedman, Jacob, additional

Published
2021
Full Text
View/download PDF

76. A nationwide assessment of hepatocellular adenoma resection: Indications and pathological discordance.

Author

Haring, Martijn P. D., Elfrink, Arthur K. E., Oudmaijer, Christiaan A. J., Andel, Paul C. M., Furumaya, Alicia, de Jong, Nenke, Willems, Colin J. J. M., Huits, Thijs, Sijmons, Julie M. L., Belt, Eric J. T., Bosscha, Koop, Consten, Esther C. J., Coolsen, Mariëlle M. E., van Duijvendijk, Peter, Erdmann, Joris I., Gobardhan, Paul, de Haas, Robbert J., van Heek, Tjarda, Hwai-Ding Lam, and Leclercq, Wouter K. G.

Subjects
CONTRAST-enhanced magnetic resonance imaging, PREOPERATIVE risk factors, LIVER tumors, LOGISTIC regression analysis
Abstract

Hepatocellular adenomas (HCAs) are benign liver tumors associated with bleeding or malignant transformation. Data on the indication for surgery are scarce. We analyzed indications and outcome of patients operated for HCAs < 50mm compared to HCAs = 50 mm. Changes in final postoperative diagnosis were assessed. We performed a retrospective study that included patients who underwent resection for (suspected) HCAs in the Netherlands from 2014 to 2019. Indication for resection was analyzed and stratified for small (<50 mm) and large (=50 mm) tumors. Logistic regression analysis was performed on factors influencing change in tumor diagnosis. Out of 222 patients who underwent surgery, 44 (20%) patients had a tumor <50 mm. Median age was 46 (interquartile range [IQR], 33-56) years in patients with small tumors and 37 (IQR, 31-46) years in patients with large tumors (p = 0.016). Patients with small tumors were more frequently men (21% vs. 5%, p = 0.002). Main indications for resection in patients with small tumors were suspicion of (pre) malignancy (55%), (previous) bleeding (14%), and male sex (11%). Patients with large tumors received operations because of tumor size >50mm (52%), suspicion of (pre)malignancy (28%), and (previous) bleeding (5.1%). No difference was observed in HCA-subtype distribution between small and large tumors. Ninety-six (43%) patients had a postoperative change in diagnosis. Independent risk factors for change in diagnosis were tumor size <50mm (adjusted odds ratio [aOR], 3.4; p < 0.01), male sex (aOR, 3.7; p = 0.03), and lack of hepatobiliary contrast-enhanced magnetic resonance imaging (CE-MRI) (aOR, 1.8; p = 0.04). Resection for small (suspected) HCAs was mainly indicated by suspicion of (pre)malignancy, whereas for large (suspected) HCAs, tumor size was the most prevalent indication. Male sex, tumor size <50 mm, and lack of hepatobiliary CE-MRI were independent risk factors for postoperative change in tumor diagnosis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

78. Analyzing the Estrogen Receptor Status of Liver Metastases with [18F]-FES-PET in Patients with Breast Cancer

Author

Boers, Jorianne, primary, Loudini, Naila, additional, de Haas, Robbert J., additional, Willemsen, Antoon T. M., additional, van der Vegt, Bert, additional, de Vries, Elisabeth G. E., additional, Hospers, Geke A. P., additional, Schröder, Carolina P., additional, Glaudemans, Andor W. J. M., additional, and de Vries, Erik F. J., additional

Published
2021
Full Text
View/download PDF

83. Incident Gallstones During Somatostatin Analog Treatment are Associated with Acute Biliary Complications Especially After Discontinuation

Author

Aapkes, Sophie E., de Haas, Robbert J., Bernts, Lucas H.P., Blijdorp, Charles J., Dekker, Sosha E.I., van Gastel, Maatje D.A., Meijer, Esther, Veldman, Abigail, Drenth, J. P.H., Gansevoort, R. T., Aapkes, Sophie E., de Haas, Robbert J., Bernts, Lucas H.P., Blijdorp, Charles J., Dekker, Sosha E.I., van Gastel, Maatje D.A., Meijer, Esther, Veldman, Abigail, Drenth, J. P.H., and Gansevoort, R. T.

Abstract

Introduction: Gallstones are a known adverse effect of somatostatin analogs, but the exact incidence and clinical implications are unknown. Objectives: The aim of this study was to investigate the incidence of gallstones on imaging and related complications in unbiased trial data. Methods: Data from the DIPAK 1 trial, in which 305 polycystic kidney disease patients were randomized to standard of care (SoC) or lanreotide for 120 weeks, were used. Magnetic resonance imaging (MRI) was performed at baseline and end of treatment and was assessed for the presence, number, and size of gallstones. For all patients who had gallstones at the end of the trial, we obtained follow-up after the trial. Results: Of 249 patients with data available, 11 patients randomized to lanreotide and four randomized to SoC had gallstones at baseline. During the study, new gallstones were formed in 19/124 patients using lanreotide (15%) and 1/125 patients receiving SoC (1%). The odds ratio for gallstone formation with lanreotide use was 25.9 (95% confidence interval 3.37–198.8; p < 0.001). Gallstones during lanreotide treatment were multiple (> 20 stones in 69% of patients) and small (≤ 3 mm in 63% of patients). Of the 19 patients with incident gallstones during lanreotide treatment, 9 experienced gallstone-associated complications, 8 of whom experienced gallstone-associated complications after discontinuation of treatment (median time after discontinuation 2.5 years). In patients with gallstones at baseline and in patients receiving SoC, no complications occurred. Conclusions: Treatment with a somatostatin analog leads to the formation of multiple, small gallstones that are associated with severe complications, especially after discontinuation of therapy. Clinical Trial Registry Website and Trial Number: ClinicalTrials.gov (https://clinicaltrials.gov); NCT01616927.

Published
2021

88. Hypothermic Machine Perfusion in Liver Transplantation — A Randomized Trial

Author

van Rijn, Rianne, primary, Schurink, Ivo J., additional, de Vries, Yvonne, additional, van den Berg, Aad P., additional, Cortes Cerisuelo, Miriam, additional, Darwish Murad, Sarwa, additional, Erdmann, Joris I., additional, Gilbo, Nicholas, additional, de Haas, Robbert J., additional, Heaton, Nigel, additional, van Hoek, Bart, additional, Huurman, Volkert A.L., additional, Jochmans, Ina, additional, van Leeuwen, Otto B., additional, de Meijer, Vincent E., additional, Monbaliu, Diethard, additional, Polak, Wojciech G., additional, Slangen, Jules J.G., additional, Troisi, Roberto I., additional, Vanlander, Aude, additional, de Jonge, Jeroen, additional, and Porte, Robert J., additional

Published
2021
Full Text
View/download PDF

89. Prediction of Non-Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients with 18 F-FDG PET Radiomics Based Machine Learning Classification.

Author

Beukinga, Roelof J., Poelmann, Floris B., Kats-Ugurlu, Gursah, Viddeleer, Alain R., Boellaard, Ronald, de Haas, Robbert J., Plukker, John Th. M., and Hulshoff, Jan Binne

Subjects
ESOPHAGEAL cancer, RADIOMICS, MACHINE learning, CANCER patients, FEATURE extraction
Abstract

Background: Approximately 26% of esophageal cancer (EC) patients do not respond to neoadjuvant chemoradiotherapy (nCRT), emphasizing the need for pre-treatment selection. The aim of this study was to predict non-response using a radiomic model on baseline 18F-FDG PET. Methods: Retrospectively, 143 18F-FDG PET radiomic features were extracted from 199 EC patients (T1N1-3M0/T2–4aN0-3M0) treated between 2009 and 2019. Non-response (n = 57; 29%) was defined as Mandard Tumor Regression Grade 4–5 (n = 44; 22%) or interval progression (n = 13; 7%). Randomly, 139 patients (70%) were allocated to explore all combinations of 24 feature selection strategies and 6 classification methods towards the cross-validated average precision (AP). The predictive value of the best-performing model, i.e AP and area under the ROC curve analysis (AUC), was evaluated on an independent test subset of 60 patients (30%). Results: The best performing model had an AP (mean ± SD) of 0.47 ± 0.06 on the training subset, achieved by a support vector machine classifier trained on five principal components of relevant clinical and radiomic features. The model was externally validated with an AP of 0.66 and an AUC of 0.67. Conclusion: In the present study, the best-performing model on pre-treatment 18F-FDG PET radiomics and clinical features had a small clinical benefit to identify non-responders to nCRT in EC. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

99. Kidney Infarction in Patients With COVID-19

Author

Post, Adrian, primary, den Deurwaarder, Edwin S.G., additional, Bakker, Stephan J.L., additional, de Haas, Robbert J., additional, van Meurs, Matijs, additional, Gansevoort, Ron T., additional, and Berger, Stefan P., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results